Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
25 Octubre 2021 - 3:00PM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines
company focused on the development of infectious disease vaccines
and significant opportunities within liver and respiratory rare
diseases, today announced that it will release its financial
results for the third quarter ended September 30, 2021 after the
market close on Monday November 8, and will also host a conference
call and webcast at 4:30 pm Eastern Standard Time on November 8,
2021.
Monday, November 8th @ 4:30 p.m.
EST
Domestic: 877-407-0784
International: 201-689-8560
Conference ID: 13724305
Webcast:
https://78449.themediaframe.com/dataconf/productusers/vvdb/mediaframe/47084/indexl.html
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a clinical-stage mRNA
medicines and vaccines company with enabling technologies: (i)
LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology and
(iii) mRNA drug substance along with drug product manufacturing
expertise. Arcturus’ diverse pipeline of RNA therapeutic and
vaccine candidates includes mRNA vaccine programs for SARS-CoV-2
(COVID-19) and Influenza, and other programs to potentially treat
ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis
along with partnered programs including glycogen storage disease
type III, hepatitis B Virus, and non-alcoholic steatohepatitis
(NASH). Arcturus’ versatile RNA therapeutics platforms can be
applied toward multiple types of nucleic acid medicines including
messenger RNA, small interfering RNA, replicon RNA, antisense RNA,
microRNA, DNA, and gene editing therapeutics. Arcturus’
technologies are covered by its extensive patent portfolio (patents
and patent applications issued in the U.S., Europe, Japan, China
and other countries). Arcturus’ commitment to the development of
novel RNA therapeutics has led to collaborations with Janssen
Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies
of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda
Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics
Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation.
For more information visit www.ArcturusRx.com. In addition, please
connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211025005719/en/
IR and Media Contacts Arcturus Therapeutics Deepankar Roy
(858) 900-2682 IR@ArcturusRx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024